ADAM and EMMPRIN: a promising couple for more prognostic precision in patients with gastric cancer

Gastric cancer is still a highly problematic tumor entity. Even in early stages, individual clinical prognosis can be rather poor, and limited response to neo-adjuvant and adjuvant therapeutics still remains to be a considerable problem. For these and other instances, powerful molecular markers able to more precisely predict the individual risk for tumor recurrence and metastasis for the individual, as well as the probability to respond to certain types of therapeutics are still desperately needed.